| 配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2026年度: 1,950千円 (直接経費: 1,500千円、間接経費: 450千円)
2025年度: 1,690千円 (直接経費: 1,300千円、間接経費: 390千円)
2024年度: 1,040千円 (直接経費: 800千円、間接経費: 240千円)
|
|---|
| 研究開始時の研究の概要 |
95% of the world's three major infectious diseases, malaria, occur in Africa. I reported for the first time that resistance to first-line drug artemisinin has appeared in Africa (N Eng J Med, 2021, first author). Current artemisinin resistance cutoff is based on a study in Asia. However, unlike in Asia, people in Africa have a high level of acquired malaria-immunity, so some resistant parasites are eliminated by immunity.
Applying Asia cutoffs to Africa risks underestimating resistance. Therefore, a novel cutoff for Africa will be developed and used to develop reliable resistance gene markers.
|
